154 related articles for article (PubMed ID: 36300771)
1. Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex-An update.
Balestri R; Rizzoli L; Pedrolli A; Urru SAM; Rech G; Neri I; Girardelli CR; Magnano M
J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):474-487. PubMed ID: 36300771
[TBL] [Abstract][Full Text] [Related]
2. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.
Balestri R; Neri I; Patrizi A; Angileri L; Ricci L; Magnano M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):14-20. PubMed ID: 25174683
[TBL] [Abstract][Full Text] [Related]
3. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.
Tanaka M; Wataya-Kaneda M; Nakamura A; Matsumoto S; Katayama I
Br J Dermatol; 2013 Dec; 169(6):1314-8. PubMed ID: 23909960
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
[TBL] [Abstract][Full Text] [Related]
5. Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence.
Cortell Fuster C; Martínez Gómez MA; Cercós Lleti AC; Climente Martí M
J Dermatolog Treat; 2022 Jun; 33(4):1804-1810. PubMed ID: 33821748
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin.
Kaufman McNamara E; Curtis AR; Fleischer AB
J Dermatolog Treat; 2012 Feb; 23(1):46-8. PubMed ID: 20673154
[TBL] [Abstract][Full Text] [Related]
7. A survey of patients with facial angiofibromas associated with tuberous sclerosis complex: Short-, medium- and long-term efficacy and safety of topical rapamycin.
Sigg N; Fouquet J; Morin D; Farges D; Vrignaud S; Martin L
Ann Dermatol Venereol; 2023 Dec; 150(4):270-273. PubMed ID: 37821253
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex.
Lee YI; Lee JH; Kim DY; Chung KY; Shin JU
Dermatology; 2018; 234(1-2):13-22. PubMed ID: 29925060
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I
JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201
[TBL] [Abstract][Full Text] [Related]
10. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report.
Dill PE; De Bernardis G; Weber P; Lösch U
Pediatr Neurol; 2014 Jul; 51(1):109-13. PubMed ID: 24810875
[TBL] [Abstract][Full Text] [Related]
11. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.
Foster RS; Bint LJ; Halbert AR
Australas J Dermatol; 2012 Feb; 53(1):52-6. PubMed ID: 22309333
[TBL] [Abstract][Full Text] [Related]
12. Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus.
Wang S; Liu Y; Wei J; Zhang J; Wang Z; Xu Z
Pediatr Dermatol; 2017 Sep; 34(5):572-577. PubMed ID: 28771801
[TBL] [Abstract][Full Text] [Related]
13. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity.
Wataya-Kaneda M; Tanaka M; Nakamura A; Matsumoto S; Katayama I
Br J Dermatol; 2011 Oct; 165(4):912-6. PubMed ID: 21692771
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of topical rapamycin-calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double-blind, randomized clinical trial.
Chen PL; Hong JB; Shen LJ; Chen YT; Wang SJ; Liao YH
Br J Dermatol; 2020 Oct; 183(4):655-663. PubMed ID: 32064596
[TBL] [Abstract][Full Text] [Related]
15. A Review of Topical Sirolimus for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex.
Dao DD; Pixley JN; Akkurt ZM; Feldman SR
Ann Pharmacother; 2024 Apr; 58(4):428-433. PubMed ID: 37386842
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment of disfiguring facial angiofibromas in tuberous sclerosis complex with surgical debulking and topical sirolimus.
Patterson JL; Iyengar S; Catasus C; Kolodney JA; Zinn Z
Cutis; 2020 Dec; 106(6):307-308. PubMed ID: 33471874
[TBL] [Abstract][Full Text] [Related]
17. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response.
Truchuelo T; Díaz-Ley B; Ríos L; Alcántara J; Jaén P
Dermatol Online J; 2012 Jan; 18(1):15. PubMed ID: 22301052
[TBL] [Abstract][Full Text] [Related]
18. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus].
Tiedemann Svendsen M; Bygum A; Hansen LK; Broesby-Olsen S
Ugeskr Laeger; 2013 Oct; 175(43):2569-70. PubMed ID: 24629155
[TBL] [Abstract][Full Text] [Related]
19. Use of mTOR inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex.
Farges D; Sigg N; Ville D; Martin L
Arch Pediatr; 2022 Dec; 29(5S):5S20-5S24. PubMed ID: 36585067
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
Wataya-Kaneda M; Ohno Y; Fujita Y; Yokozeki H; Niizeki H; Ogai M; Fukai K; Nagai H; Yoshida Y; Hamada I; Hio T; Shimizu K; Murota H
JAMA Dermatol; 2018 Jul; 154(7):781-788. PubMed ID: 29800026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
